title: Hydroxyprogesterone caproate injection (makena) one year later: to compound or not to compound that is the question.
abstract: Preterm births have increased by 27% over the last decade in the U.S. The main ingredient in Makena, 17P, is less expensive at compounding pharmacies, but this method is not FDA-approved. The authors discuss the quality, safety, and use of Makena and compounded 17P; the potential for liability; cost considerations; and recommended restrictions for the product's use.
authors.forename: Yesha
authors.initials: Y
authors.lastname: Patel
authors.forename: Martha M
authors.initials: MM
authors.lastname: Rumore